Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
J Leukoc Biol ; 116(1): 186-196, 2024 Jun 28.
Artículo en Inglés | MEDLINE | ID: mdl-38648512

RESUMEN

Transarterial embolization, the first-line treatment for hepatocellular carcinoma, does not always lead to promising outcomes in all patients. A better understanding of how the immune lymphocyte changes after transarterial embolization might be the key to improve the efficacy of transarterial embolization. However, there are few studies evaluating immune lymphocytes in transarterial embolization patients. Therefore, we aimed to evaluate the short- and long-term effects of transarterial embolization on lymphocyte subsets in patients with hepatocellular carcinoma to identify those that predict transarterial embolization prognosis. Peripheral blood samples were collected from 44 patients with hepatocellular carcinoma at the following time points: 1 d before the initial transarterial embolization, 3 d after the initial transarterial embolization, and 1 mo after the initial transarterial embolization and subjected to peripheral blood mononuclear cell isolation and flow cytometry. Dynamic changes in 75 lymphocyte subsets were recorded, and their absolute counts were calculated. Tumor assessments were made every 4 to 6 wk via computed tomography or magnetic resonance imaging. Our results revealed that almost all lymphocyte subsets fluctuated 3 d after transarterial embolization, but only Tfh and B cells decreased 1 mo after transarterial embolization. Univariate and multivariate Cox regression showed that high levels of Th2 and conventional killer Vδ2 cells were associated with longer progressive-free survival after transarterial embolization. Longer overall survival after transarterial embolization was associated with high levels of Th17 and viral infection-specific Vδ1 cells and low levels of immature natural killer cells. In conclusion, transarterial embolization has a dynamic influence on the status of lymphocytes. Accordingly, several lymphocyte subsets can be used as prognostic markers for transarterial embolization.


Asunto(s)
Carcinoma Hepatocelular , Embolización Terapéutica , Neoplasias Hepáticas , Humanos , Carcinoma Hepatocelular/terapia , Carcinoma Hepatocelular/patología , Carcinoma Hepatocelular/inmunología , Neoplasias Hepáticas/terapia , Neoplasias Hepáticas/patología , Neoplasias Hepáticas/inmunología , Masculino , Femenino , Persona de Mediana Edad , Embolización Terapéutica/métodos , Pronóstico , Anciano , Linfocitos/inmunología , Linfocitos/patología , Subgrupos Linfocitarios/inmunología , Recuento de Linfocitos
2.
Small ; 13(40)2017 10.
Artículo en Inglés | MEDLINE | ID: mdl-28845916

RESUMEN

Tungsten ditelluride (WTe2 ) is a semimetal with orthorhombic Td phase that possesses some unique properties such as Weyl semimetal states, pressure-induced superconductivity, and giant magnetoresistance. Here, the high-pressure properties of WTe2 single crystals are investigated by Raman microspectroscopy and ab initio calculations. WTe2 shows strong plane-parallel/plane-vertical vibrational anisotropy, stemming from its intrinsic Raman tensor. Under pressure, the Raman peaks at ≈120 cm-1 exhibit redshift, indicating structural instability of the orthorhombic Td phase. WTe2 undergoes a phase transition to a monoclinic T' phase at 8 GPa, where the Weyl states vanish in the new T' phase due to the presence of inversion symmetry. Such Td to T' phase transition provides a feasible method to achieve Weyl state switching in a single material without doping. The new T' phase also coincides with the appearance of superconductivity reported in the literature.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...